Advanced drug delivery reviews: Enzyme prodrug therapy

Advanced Drug Delivery Reviews

Volumn 22, Issue 3, 1996, Pages 269-288

  Sherwood, Roger F ^a,b  

^a Magdalen Centre   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

ADEPT; cancer; enzyme; GDEPT; prodrug; targeting; VDEPT

Indexed keywords

ANTIBODIES; CYTOLOGY; DISEASES; ENZYMES; GENES; VIRUSES;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER; CYTOTOXIC AGENTS; GENE DIRECTED ENZYME PRODRUG THERAPY; VIRUS DIRECTED ENZYME PRODRUG THERAPY;

DRUG THERAPY;

ALKALINE PHOSPHATASE; ALPHA GALACTOSIDASE; ANTINEOPLASTIC AGENT; BETA GLUCOSIDASE; BETA GLUCURONIDASE; BETA LACTAMASE; CANCER ANTIBODY; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE B; CARBOXYPEPTIDASE G2; CYTOSINE DEAMINASE; DEACETYLVINBLASTINE 3 CARBOHYDRAZIDE; DOXORUBICIN; ENZYME; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; NITROREDUCTASE; PENICILLIN AMIDASE; PRODRUG; TEGAFUR; THYMIDINE KINASE; TUMOR ANTIGEN; UNINDEXED DRUG;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; CANCER; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RELEASE; DRUG TARGETING; ENZYME MECHANISM; ENZYME SPECIFICITY; GENE THERAPY; HUMAN; METABOLIC ACTIVATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030589537     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00450-4     Document Type: Review

References (104)

1. 2 from Pseudomonas sp. strain RS-16: Use of a novel triazine dye affinity method. Eur. J. Biochem. 148, 447-453.
2. 2 gene and its expression in Escherichia coli and Pseudomonas putida. J. Bacteriol. 156, 1222-1227.
3. 2. Gene 31, 31-38.
4. [4] Kalghatgi, K.K. and Bertino, J.R. (1981) Folate degrading enzymes: A review with special emphasis on carboxypeptidase G. In: J.S. Holcenberg and J. Roberts (Eds.), Enzymes as Drugs. Wiley, New York, pp. 77-102.
5. 2 and cytotoxicity of the conjugate against JAR choriocarcinoma cells in vitro. Br. J. Cancer 53, 377-384.
6. 2: antibody conjugates as antitumour agents: II. In vivo localising and clearance properties in a choriocarcinoma model. Br. J. Cancer 61, 420-424.
7. [7] Bagshawe, K.D. (1987) Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer 56, 531-532.
8. [8] Bagshawe, K.D., Springer, C.J., Searle, F., Antoniw, P., Sharma, S.K., Melton, R.G. and Sherwood, R.F. (1988) A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 58, 700-703.
9. 2. J. Med. Chem. 33, 677-681.
10. [10] Springer, C.J., Bagshawe, K.D., Sharma, S.K., Searle, F., Boden, J.A., Antoniw, P., Burke, P.J., Rogers, G.T., Sherwood, R.F. and Melton, R.G. (1991) Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 27, 1361-1366.
11. [11] Bagshawe, K.D. (1989) Towards generating cytotoxic agents at cancer sites. Br. J. Cancer 60, 275-281.
12. [12] Frei, E., Teicher, B.A., Holden, S.A., Cathcart, K.N.S. and Wang, Y. (1988) Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res. 48, 6417-6423.
13. [13] Davies, D.H., Blakey, D.C., Springer, C.J., Burke. P.J., Dowell, R.I., Boyle, F.T., Melton, R.G., Connors, T.A. and Mauger, A.B. (1995) A novel bisiodo-phenol mustard prodrug, ZD 2767P, for antibody directed enzyme prodrug therapy. Proc. Am. Assoc. Cancer Res. 36, 482.
14. 2. J. Immunol. Methods 158, 49-56.
15. 2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys. 22, 1-8.
16. [16] Blakey, D.C., Sharma, S.K., Davies, D.H., Dowell, R.J., East. S.J., Springer, C.J. and Melton, R.G. (1995) ZD2767: A new system for antibody-directed enzyme prodrug therapy which causes regressions in colorectal carcinoma xenografts. Proc. Am. Assoc. Cancer Res. 36, 482.
17. 1. Cancer Res. 54, 5171-5177.
18. [18] Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, J., Rogers, G.T., Springer, C.J., Melton, R.G. and Sherwood, R.F. (1994) Galactosylated antibodies and antibody-enzyme conjugates in Antibody-Directed Enzyme Prodrug Therapy. Cancer 73, 1114-1120.
19. [19] Sharma, S.K., Bagshawe, K.D., Melton, R.G. and Sherwood, R.F. (1992) Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys. 21, 109-120.
20. [20] Moola, Z., Scawen, M.D., Atkinson, T. and Nicholls, D.J. (1994) Erwinia chrysanthemi asparaginase: epitope mapping and preparation of antigenically modified enzymes. Biochem. J. 302, 921-927.
21. 2 from Pseudomonas strain RS-16. J. Mol. Biol. 220, 17-18.
22. [22] Senter, P.D., Saulnier, M.G., Schreiber, G.J., Hirschberg, D.C., Brown, J.P., Hellstrom, I. and Hellstrom, K.E. (1988). Antitumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA 85, 4842-4846.
23. [23] Haisma, H.J., Boven, E., van Muijen, M., de Vries, R. and Pinedo, H.M. (1992). Analysis of a conjugate between anticarcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate. Cancer Immunol. Immunother., 34, 343-348.
24. [24] Doyle, T.W. and Vyas, D.M. (1990) Second generation analogs of etoposide and mitomycin C. Cancer Treat. Rev. 17, 127-131.
25. [25] Senter, P.D., Schrieber, G.J., Hirschberg, D.L., Ashe, S.A., Hellstrom, K.E. and Hellstrom, I. (1989) Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res. 49, 5789-5792.
26. [26] Sahin, U., Hartmann, F., Senter, P., Pohl, C., Engert, A., Diehl, V. and Pfreundschuh, M. (1990) Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/ anti-alkaline phosphatase monoclonal antibody. Cancer Res. 50, 6944-6948.
27. [27] Senter, P.D. (1990) Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4, 188-193.
28. [28] Wallace, P.M. and Senter, P.D. (1991) In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjugate Chem. 2, 349-352.
29. [29] Nishiyama, T., Kawamura, Y., Kawamoto, K., Matsumura, H., Ito, N., Ohyama, A., Katsuragi, T. and Sakai, T. (1985) Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res. 45, 1753-1761.
30. [30] Huennekens, F.M., Montejano, Y.D. and Vitols, K.S. (1988) Overview: Rational basis for development of fluoropyrimidine/5-formyltetrahydrofolate combination chemotherapy. In: Y. Rustum and J.J. McGuire (Eds.), The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. Advances in Experimental Medicine and Biology. Vol. 244. Plenum Press, New York, pp. 1-12.
31. [31] Manzuik, L.V., Perevodchikova, N.I., Gorbunova, V.A., Singin, A.S., Gerasimova, G.S., Bychkov, M.B., Rustum, Y.M. and Creavan, P.J. (1993) Initial clinical experience with oral ftorafur and oral 6R. S leucovorin in advanced colorectal carcinoma. Eur. J. Cancer 29A, 1793-1794.
32. [32] Senter, P.D., Su, P.C., Katsuragi, T., Sakai, T., Cosand, W.L., Hellstrom. I. and Hellstrom, K.E. (1991) Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugate. Bioconjugate Chem. 2, 447-451.
33. [33] Wallace, P.M., MacMaster, J.F., Smith, V.F., Kerr, D.E., Senter, P.D. and Cosand, W.L. (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 54, 2719-2723.
34. [34] Kerr, D.E., Garrigues, U.S., Wallace, P.M., Hellstrom, K.E., Hellstrom, I. and Senter, P.D. (1993) Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase conjugate. Bioconjugate Chem. 4, 353-357.
35. [35] Shepherd, T.A., Jungheim, L.N., Meyer, D.L. and Starling, J.J. (1991) A novel targeted delivery system utilising a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Biorg. Med. Chem. Lett. 1, 21-26.
36. [36] Jungheim, L.N., Shepherd, T.A. and Meyer. D.L. (1992) Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: Substrates for an antibody-targeted enzyme. J. Org. Chem. 57, 2334-2340.
37. [37] Meyer, D.L., Jungheim, L.N., Mikolajczyk, S.D., Shepherd, T.A., Starling, J.J. and Ahlem, C.N. (1992) Preparation and characterisation of a β-lactamase-Fab′ conjugate for the site specific activation of oncolytic agents. Bioconjugate Chem. 3, 42-48.
38. [38] Meyer, D.L., Jungheim, L.N., Law, K.L., Mikolajczyk, S.D., Shepherd, T.A., Mackenson, D.G., Briggs, S.L. and Starling, J.J. (1993) Site-specific prodrug activation by antibody-β-lactamase conjugates: Regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res. 53, 3956-3963.
39. [39] Jungheim, L.N., Shepherd, T.A. and King, J.K. (1993) Synthesis of a cephalosporin-doxorubicin antitumour prodrug: a substrate for an antibody-targeted enzyme, Heterocycles (Tokyo) 35, 329-348.
40. [40] Hudyma, T.W., Bush, K., Colson, K.L., Firestone, R.A. and King, H.D. (1993) Synthesis and release ol doxorubicin from a cephalosporin based prodrug by a β-lactamase-immunoconjugate. Biorg. Med. Chem. Lett. 3, 323-328.
41. [41] Wallace, P.M. and Senter, P.D. (1994) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Methods Find. Exp. Clin. Pharmacol. 16, 505-512.
42. HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55, 63-70.
43. [43] De Sutter, K. and Fiers, W. (1994) A bi-functional murine::human chimeric antibody with one antigen-binding arm replaced by bacterial β-lactamase. Mol. Immunol. 31, 261-267.
44. [44] Alexander, R.P., Beeley, N.R.A., O'Driscol, M., O'Neill, F.P., Millican, T.A., Pratt, A.J. and Willenbrock, F.W. (1991) Cephalosporin nitrogen mustard carbamate prodrugs for 'ADEPT'. Tetrahedron Lett. 32, 3269-3272.
45. [45] Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M. and Senter, P.D. (1992) Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjugate Chem. 3, 176-181.
46. [46] Vrudhula, V.M., Svensson, H.P., Kennedy, K.A., Senter, P.D. and Wallace, P.M. (1993) Antitumour activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconjugate Chem. 4, 334-340.
47. [47] Kerr, D.E., Senter, P.D., Burnett, W.V., Hirschberg, D.L., Hellstrom, I. and Hellstrom, K.E. (1990) Antibody-penicillin-V-amidase conjugates kill antigen-positive tumour cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol. Immunother. 31, 202-206.
48. [48] Vrudhula, V.M., Senter, P.D., Fischer, K.J. and Wallace, P.M. (1993) Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J. Med. Chem. 36, 919-923.
49. [49] Bignami, G.S., Senter, P.D., Grothaus, P.G., Fischer, K.J., Humphreys, T. and Wallace, P.M. (1992). N-(4′-hydroxylphenylacetyl)palytoxin. A palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res. 52, 5759-5764.
50. - )-ATPase in binding and actions of palytoxin on human erythrocytes. Biochim. Biophys. Acta 861, 165-176.
51. [51] Roberts, J.J., Friedlos, F. and Knox, R.J. (1986) CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. 140, 1073-1078.
52. [52] Knox, R.J., Friedlos, F., Jarman, M. and Roberts, J.J. (1988) A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2.-4-dinitrobenzamide (CB1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37, 4661-4669.
53. [53] Knox, R.J., Boland, M.P., Friedlos, F., Coles, B., Southan, C. and Roberts, J.J. (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37, 4671-4677.
54. [54] Anlezark, G.M., Melton, R.G., Sherwood, R.F., Coles, B., Friedlos, F. and Knox, R.J. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44, 2289-2295.
55. [55] Knox, R.J., Friedlos, F., Sherwood, R.F., Melton, R.G. and Anlezark, G.M. (1992) The bioactivation of 5-(aziridin-1-yl)-2.4-dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44, 2297-2301.
56. [56] Michael, N.P., Brehm, J.K., Anlezark, G.M. and Minton, N.P. (1994) Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12. FEMS Microbiol. Lett. 124, 195-202.
57. [57] Friedlos, F. and Knox, R.J. (1992) Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochem. Pharmacol. 44, 631-635.
58. [58] Knox, R.J., Friedlos, F., Jarman, M., Davies, L.C., Goddard, P., Anlezark, G.M., Melton, R.G. and Sherwood, R.F. (1995) Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 49, 1641-1647.
59. [59] Anlezark, G.M., Melton, R.G., Sherwood. R.F., Wilson, R.W., Denny, W.A., Palmer, B.D., Knox, R.J., Friedlos, F. and Williams, A. (1995) Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 50, 609-618.
60. [60] Anlezark, G., Melton, R., Sherwood, R., Knox. R., Friedlos, F., Palmer, B., Wilson, W. and Denny, W. (1994) Nitroreductase substrates as potential prodrugs for ADEPT. Br. J. Cancer 69 Suppl. XXI, 57.
61. [61] Mauger, A.B., Burke, P.J., Somani, H.H., Friedlos, F. and Knox, R.J. (1994) Self-immolative prodrugs: Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 37, 3452-3458.
62. [62] Kuefner, U., Lohrmann, U., Montejano, Y.D., Vitols, K.S. and Huennekens, F.M. (1989) Carboxypeptidase-mediated release of methotrexate from methotrexate α-peptides. Biochemistry 28, 2288-2297.
63. [63] Esswein, A., Hanseler, E., Montejano, Y., Vitols, K.S. and Huennekens, F.M. (1991) Construction and chemotherapeutic potential of carboxypeptidase-A/monoclonal antibody conjugate. Adv. Enzyme Regul. 31, 3-12.
64. [64] Haenseler, E., Esswein, A., Vitols, K.S., Montejano, Y., Mueller, B.M., Reisfeld, R.A. and Huennekens, F.M. (1992) Activation of methotrexate-α-alanine by carboxypeptidase A-monoclonal antibody conjugate. Biochemistry 31, 891-897.
65. [65] Perron, M-J. and Page, M. (1994) Synthesis of methotrexate prodrugs as an approach for drug targeting. Int. J. Oncol. 5, 907-913.
66. [66] Smal, M.A., Dong, Z., Cheung, H.T.A., Asano, Y., Escoffier. L,. Costello, M. and Tattersall, M.H.N. (1995) Activation and cytotoxicity of 2-α aminoacyl prodrugs of methotrexate. Biochem. Pharmacol. 49, 567-574.
67. [67] Connors, T.A. and Whisson, M.E. (1966) Cure of mice bearing advanced plasma cell tumours with aniline mustard: The relationship between glucuronidase activity and tumour sensitivity. Nature 210, 866-867.
68. [68] Kyle, R.A., Costa, G., Cooper, M.R., Ogawa, M., Silver, R.T., Glidewell, O. and Holland, J.F. (1973) Evaluation of aniline mustard in patients with multiple myeloma. Crit. Rev. Biochem. Mol. Biol. 33, 956-960.
69. [69] Roffler, S.R., Wang, S.M., Chern, J.W., Yeh, M.Y. and Tung, E. (1991) Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem. Pharmacol. 42, 2062-2065.
70. [70] Wang, S.M., Chern, J.W., Yeh, M.Y., Ng, Y.C., Tung, E. and Roffler, S.R. (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzymes for cancer therapy. Cancer Res. 52, 4484-4491.
71. [71] Haisma, H.J., Boven, E., van Muijen, M., de Jong, J., van der Vijgh, W.J.F. and Pinedo, H.M. (1992) A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br. J. Cancer 66, 474-478.
72. [72] Mross, K., Maesson, P., van der Vijgh, W.J.F., Gall, H., Boven, E. and Pinedo, H.M. (1988) Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol. 6, 517-526.
73. [73] Bosslet, K., Czech, J., Lovenz, P., Sedlacek, H.H., Schuermann, M. and Seemann, G. (1992) Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br. J. Cancer 65, 234-238.
74. [74] Bosslet, K., Czech, J. and Hoffmann, D. (1994). Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 54, 2151-2159.
75. [75] Andrianomenjanahary, S., Dong, X., Florent, J-C., Gaudel, G., Gesson, J-P., Jacquesy, J-C., Koch, M., Michel, S., Mondon, M., Petit, P., Renoux, B. and Tillequin, F. (1992) Synthesis of novel targeted pro-prodrugs of anthracyclines potentially activated by a monoclonal antibody galactosidase conjugate. Biorg. Med. Chem. Lett. 9, 1093-1096.
76. [76] Gesson, J-P., Jacquesy, J-C., Mondon, M., Petit, P., Renoux, B., Andrianomenjanahary, S., Dufat-Trink Van, H., Koch, M., Michel, S., Tillequin, F., Florent, J-C., Monneret, C., Bosslet, K., Czech, J. and Huffman, D. (1994) Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anti-Cancer Drug Des. 9, 409-423.
77. [77] Rowlinson-Busza, G., Bamias, A., Kraus, T. and Epenetos, A.A. (1992) Antibody-guided enzyme nitrile therapy (AGENT): in vitro cytotoxicity and in vivo localisation. In: A.A. Epenetos (Ed.), Monoclonal Antibodies. Applications in Clinical Oncology. Chapman and Hall. London, pp. 111-118.
78. [78] Bamias, A. and Epenetos. A.A. (1992) Two step strategies for the diagnosis and treatment of cancer with bioconjugates. Antibody Immunoconjugates Radiopharm. 5, 385-395.
79. [79] Muzykantov, V.R., Sakharov, D.V., Sinitsyn, V.V., Domogatsky, S.P., Goncharov, N.V. and Danilov, S.M. (1988) Specific killing of human endothelial cells by antibody-conjugated glucose oxidase. Anal. Biochem. 169, 383-389.
80. [80] Stanislawski, M., Rousseau, V., Goavec, M. and Ito, M. (1989) Immunotoxins containing glucose oxidase and lacteroperoxidase with tumoricidal properties: In vitro killing effectiveness in a mouse plasmacytoma cell model. Cancer Res. 49, 5497-5504.
81. [81] Battelli, M.G., Abbondanza, A., Tazzari, P.L., Dinota, A., Rizzi, S., Grassi, G., Gobbi, M. and Stirpe, F. (1988) Selective cytotoxicity of an oxygen radical-generating enzyme conjugated to a monoclonal antibody. Clin. Exp. Immunol. 73, 128-133.
82. [82] Muzykantov, V.R., Trubetskaya, O.V., Puchnina, E.A., Sakharov, D.V. and Domogatsky, S.P. (1990) Cyotoxicity of glucose oxidase conjugated with antibodies to target cells: Killing efficiency depends on the conjugate internalisation. Biochim. Biophys. Acta 1053, 27-31.
83. [83] Takeda Chemical Industries Ltd. (1991) World Patent Application WO 91/09134.
84. [84] Sims, M.A. (1994) Azoreductases in cancer therapy. Ph.D. Thesis, Open University, Milton Keynes, UK.
85. [85] Connors, T.A. (1986) Prodrugs in cancer chemotherapy, Xenobiotica 16, 975-988.
86. [86] Austin, E.A. and Huber, B.E. (1993) A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol. Pharmacol. 43, 380-387.
87. [87] Mullen, C.A., Kilstrup, M. and Blaese, R.M. (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89, 33-37.
88. [88] Huber, B.E., Austin, E.A., Goode, S.S., Knick, V.C., Tibbels, S. and Richards, C.A. (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53, 4619-4626.
89. [89] Consalvo, M., Mullen, C.A., Modesti, A., Musiani, P., Allione, A., Cavallo, F., Giovarelli, M. and Forni, G. (1995) 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol. 154, 5302-5312.
90. [90] Matthews, T. and Boehine, R. (1988) Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10. 5490-5494.
91. [91] Moolten, F. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 6, 5276-5281.
92. [92] Vile, R.G. and Hart, I.R. (1993) Use of tissue specific expression of the Herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53, 3860-3864.
93. [93] Bonnekoh, B., Greenhalgh, D.A., Bundman, D.S., Eckhardt, J.N., Langley, M.A., Chen, S-H., Woo, S.L.C. and Roop, D.R. (1995) Inhibition of melanoma growth by adenoviralmediated HSV thymidine kinase gene transfer in vivo. J. Invest. Dermatol. 104, 313-317.
94. [94] Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, I., Kawase, I., Oikawa, S. and Kishimoto, T. (1994) Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of Herpes simplex virus thymidine kinase gene. Cancer Res. 54, 5258-5261.
95. [95] Yoshida, K., Kawami, H., Yamaguchi, Y., Kuniyasu, H., Nishiyama, M., Hirai, T., Yanagihara, K., Tahara, E. and Toge, T. (1995) Retrovirally transmitted gene therapy for gastric carcinoma using Herpes simplex thymidine kinase gene. Cancer Suppl. 75, 1467-1471.
96. [96] DiMaio, J.M., Clary, B.M., Via, D.F., Coveney, E., Pappas, T.N. and Lyerly, H.K. (1994) Directed enzyme prodrug gene therapy for pancreatic cancer in vivo. Surgery 116, 205-213.
97. [97] Chen, S-H., Chen, X.H.L., Wang. Y., Kosai, K-I., Finegold, M.J., Rich, S.S. and Woo, S.L.C. (1995) Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc. Natl. Acad. Sci. USA 92, 2577-2581.
98. [98] Culver, K.W., Ram, Z., Watlbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
99. [99] Ram, Z., Culver, K.W., Wallbridge, S., Blaese, R.M. and Oldfield, E.H. (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
100. [100] Culver, K.W., Van Gilder, J., Link, C.J., Carlstrom, T., Buroker, T., Yuh, W., Koch, K., Schabold, K., Doornbas, S., Wetjen, B. and Blease, R.M. (1994) Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the Herpes simplex thymidine kinase gene/ganciclovir system. Hum. Gene Ther. 5, 343-379.
101. [101] Bridgewater, J., Minton, N.P., Michael, N.P., Knox, R., Springer, C. and Collins, M. (1995) Expression of bacterial nitroreductase in mammalian cells renders them selectively sensitive to killing by CB 1954. Eur. J. Cancer 31, 2362-2370.
102. [102] Sikora, K. (1993) Gene therapy for cancer. Trends Biotechnol. 11, 197-201.
103. [103] Freeman, S.M., Abboud, C.N., Whartenby, K.A., Packman, C.H., Koeplin, D.S., Moolten, F.L. and Abraham, G.N. (1993) The 'bystander effect': tumour regression when a fraction of tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
104. [104] Campbell, D.A., Gong, B., Kochersperger, L.M., Yonkovich, S., Gallop, M.A. and Schultz, P.G. (1994) Antibody-catalyzed prodrug activation. J. Am. Chem. Soc. 116, 2165-2166.